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ABSTRACT: Encouraging results are emerging from systems that exploit Toll like receptor 
(TLR) signaling, nanotechnology, checkpoint inhibition and molecular imaging for cancer 
immunotherapy. A major remaining challenge is developing effective, durable and tumour-
specific immune responses without systemic toxicity. Here, we report a simple and versatile 
system based on synergistic activation of immune responses and direct cancer cell killing by 
combined TLR ligation using polyIC as TLR3 and imiquimod (R837) as TLR7 agonist, in 
combination with the model antigen ovalbumin (OVA) and phospholipid micelles loaded with 
zinc-doped iron oxide magnetic nanoparticles (MNPs). The combination of TLR agonists 
triggered a strong innate immune response in the lymph nodes (LNs) without systemic release of 
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pro-inflammatory cytokines. The vaccines showed excellent efficacy against aggressive B16-F10 
melanoma cells expressing OVA, which was improved with immune checkpoint abrogation of 
the immunosuppressive programmed death-ligand 1 (PD-L1) at the level of the cancer cells. By 
magnetic resonance (MR) and nuclear imaging we could track the vaccine migration from the 
site of injection to LNs and tumour. Overall, we show this synergistic TLR agonists and their 
combination with MNPs and immune checkpoint blockade to have considerable potential for 
preclinical and clinical development of vaccines for cancer immunotherapy. 
 
Introduction 
Nanoparticles (NPs) used as delivery vehicles of single chemotherapy drugs have led so far to 
nanomedicines that mainly decrease treatment-induced side effects in patients.[1–3] Although 
NPs have also been used as a promising platform for improving combination drug therapy, 
enabling multidrug treatments that are limited by lack of efficacy and toxicity concerns,[4] 
improving the overall survival of patients with these systems remains a major challenge. 
These cancer nanomedicines are still severely limited by the barriers and characteristics of the 
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tumour microenvironment in each cancer and metastasis type, and by their unwanted 
encounters with the immune system.[5,6] 
As nanomedicine matures and the understanding of the immune system deepens, a growing 
number of studies are beginning to focus on engineering nanomaterials that can be applied for 
modulating and controlling/enhancing immune responses to improve therapies and treatments for 
cancer, infectious disease, and autoimmunity.[7–16],[17] Advancing the development of such 
immunomodulatory drug-loaded NPs targeting immune cells offers the advantage that drug 
payload delivery to even a small fraction of immune cells may be enough to achieve robust 
antitumour efficacy.[18] This is because immune cells can extensively proliferate and acquire the 
capacity to generate effective antitumour responses with memory against cancer cells through 
coordinated activation of innate and adaptive immune responses upon contact with the 
immunomodulatory NP. This offers unique and intriguing possibilities for tackling metastatic 
disease and developing durable, long-term defense against cancer – the holy grail of cancer 
research. Intrinsic imaging features of drug vehicles are ideal for evaluation of drug delivery 
efficiency and guiding and non-invasive monitoring of treatment responses. Although immune 
modulating gold NPs have been developed to enable computed tomography (CT) tracking, the 
amount of NP that has to be administered is too high for practical clinical applications.[19] Iron 
oxide NPs are particularly well-suited for this application, for they have already been approved 
for human use as MRI contrast agents and as iron supplements.[20] This is because they have 
excellent biodegradability in vivo, with the iron from NPs metabolized and incorporated into the 
body’s iron store.[21–23] However, the need for high NP concentrations is also a challenge, 
leading to efforts to synthetically enhance the magnetic properties of iron oxide NPs to optimize 
their tracking by MRI.[24,25] Imaging aside, iron oxide NPs offer innovative options to harness 
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the full potency of immunotherapy agents while eliminating systemic toxicity. Recent studies 
have shown that the interaction of phagocytes with iron oxide NPs such as ferumoxytol can lead 
to tumour growth inhibition.[26] Furthermore, MNPs provide also possibilities for introducing 
new mechanisms for controlling the release, cellular fate, and biodistribution of these drugs 
using external magnetic stimulated manipulations such as magnetic field guided localization and 
hyperthermia to enhance delivery and/or combined therapeutic effects. Although none of these 
mechanisms have been exploited in cancer immunotherapy and in this study, a growing number 
of reports are providing experimental demonstration of the potential of these magnetism-based 
mechanisms for precision drug delivery and combinatorial therapy in chemotherapy.[27]  
For effective use of MNPs in cancer immunotherapy there is considerable potential in targeting 
antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs).[28] DCs in 
particular represent an ideal target because they reside in peripheral tissues and in lymph nodes 
(LNs), where they act as sentinels and serve as pivotal bridge between innate and adaptive 
immunological responses.[29] Many of these responses are triggered by recognition of specific 
molecules by TLRs on DCs.[30–33] Hence, TLR ligands (agonists and antagonists) are 
increasingly being used in the development and engineering of synthetic vaccines to combat 
infectious diseases and cancer.[34]-[35] However, a view that is emerging from systems biology 
approaches to study innate immunity is that precise spatial and temporal control of the immune 
responses is critically important. In particular, the cellular localization of TLR receptors has 
important consequences for ligand accessibility and can also have an effect on the downstream 
signaling events regulating the immune response.[36] Moreover, it has been shown that although 
TLR agonists individually may be overlooked at certain low doses, the host appears to have 
evolved to recognize some of these ligands together as a combinatorial assault which triggers 
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more vigorous immune responses.[37–40] This way, the immune system can rapidly respond to 
the potential threat, preventing a considerable infection (or potentially a tumour) from being 
established. Among all the TLRs, those involved in the recognition of nucleic acids such as 
TLR3 and TLR7 are localized within endolysosomal compartments and have been shown to 
synergize,[41] making them ideal for targeting through NP delivery. Even as single adjuvants, 
TLR3 and TLR7 agonists are included in the National Cancer Institute's ranking of 
immunotherapeutic agents with the highest potential to boost cancer immunotherapy 
outcomes.[42] Apart from targeted delivery of TLR agonists to DCs,[43] underlying the current 
difficulty to achieve effective antitumour responses are cancer cells expressing suboptimal 
tumour antigen levels.[44] The problem may be overcome if the NP also delivers tumour antigen 
to the LN-resident DCs so that they can activate and properly present antigen to T-cells to trigger 
a high-avidity antitumour response. However, tumours can actively suppress the tumour-directed 
cytotoxic T-lymphocyte (CTL) function expressing the transmembrane protein PD-L1, which 
upon binding to PD-1 expressed on the surface of activated CTLs turns off the activated 
lymphocytes.[45,46] Against this, one strategy would be to generate or enhance existing tumour-
specific CD8+ T-cell responses via the combinatorial use of particle-delivery of TLR agonists 
and tumour antigen and antibodies that block the PD-L1/PD-1 T-cell inhibitory interactions (i.e., 
immune checkpoint blockade).   
In order to enhance the antigenicity, immunogenicity and efficacy of the particle-based vaccine, 
circumstantial evidence suggests it might be important to exploit both slow and fast delivery of 
adjuvant and antigen to the target cells using both small and large particles. Studies have shown 
that although NP-enabled direct and quick delivery of vaccine components to DCs in the 
draining LNs is beneficial,[12,47] rapid cell uptake or clearance from the administration site 
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might limit the effectiveness. It is known that inflammatory signals are most effective when they 
are sustained for several days and that the slow wave of antigen-bearing DCs moving from the 
skin to the LNs is also required to induce full-fledge effector responses.[40,48–50] Moreover, 
microparticles carrying the synthetic TLR3 agonist polyinosinic-polycytidylic acid (polyIC) 
proved to be more immunogenic than nanoparticles when injected intranodally[51] for their 
ability to form an extracellular depot that confers sustained released and prolonged exposure of 
the TLR3 agonist in the lymphoid tissue. 
Here, we set out to investigate and enhance the antitumour efficacy of TLR agonist treatments 
combining polyIC with the TLR7 agonist imiquimod (R837) using a versatile and easy to 
construct micellar MNP-based drug delivery system along with immune checkpoint abrogation 
at the level of the cancer cells (Scheme 1). In this new vaccine delivery system we incorporate 
small (5 nm) ZnxFe3-xO4 NPs, which creates the opportunity for non-invasive vaccine 
localization in vivo. We first optimize and significantly increase the overall magnetization of the 
ZnxFe3-xO4 NPs by zinc(II) doping, improving the spin–spin relaxation rate (R2), hence the MRI 
detection sensitivity of the vaccine delivery vehicles by three to four times. Next, we show that 
polyIC and imiquimod form polyIC-R837 complexes with R837 intercalation into the polyIC 
dsRNA structure, which provide synergistic and complementary antitumour effects linked to 
enhanced activation of antigen presenting cells and direct cancer cell killing. We finally develop 
and test the MNP-filled micellar system biofunctionalized with polyIC-R837 complexes and the 
model tumour antigen ovalbumin (OVA), with the hypothesis that it would confer both fast and 
sustained delivery of this cargo from the subcutaneous injection site to lymphoid tissue and 
tumour due to the different tendency shown to aggregate depending on the surface 
biofunctionalization. The results show that the combination of polyIC and R837 creates a very 
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potent and effective adjuvant which, when co-administered with OVA, provides robust 
protective antitumour immunity against the highly aggressive B16-F10(OVA) melanoma 
challenge, despite its high expression of immune inhibitory PD-L1. Moreover, we show that the 
antitumour immunity is improved by the MNP-filled micellar system and by prevention of PD-
L1/PD-1 T-cell inhibitory interactions, for which we generated a B16-F10 melanoma cell line 
with silenced PD-L1. Finally, we could detect differences in the migration of the polyIC-R837- 
and OVA-carrying MNP-filled micelles combining MR and SPECT/CT imaging thanks to the 
significantly increased overall magnetization and high affinity of the MNP micelle core for 67Ga 
radionuclide. Our results highlight the promising possibility of using polyIC-R837 complexes, 
micellar MNP-based drug delivery systems and checkpoint inhibition to generate protective 
antitumour responses as a broadly applicable, versatile and effective strategy for cancer 
immunotherapy, in particular when they are combined. These results along with the simplicity 
and versatility of the system provide an excellent framework for future clinical translation.  
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Scheme 1. Self-assembly achieved by simple physical mixture of the vaccine and nanovaccine 
components promotes effective drug synergy, delivery and imaging. Adjuvant and tumour 
antigen uptake by DCs at site of injection and/or via direct trafficking to LNs is able to activate 
potent and long lasting immunity against the B16-F10(OVA) melanoma cells, in particular when 
the expression of PD-L1 is downregulated. 
  
Results  
Synthesis and characterization of PEGylated phospholipid-encapsulated ZnxFe3-xO4 NPs: 
mZnSPION and mSPION. Small (5 nm) magnetite and zinc-doped magnetic nanoparticles 
(ZnxFe3-xO4 MNPs, ZnSPION) were prepared leveraging the need for high MR contrast for 
tracking with a desirable pathway for MNP removal,[52,53] after they have coordinated the 
antitumour immune responses. TEM images of the prepared hydrophobic Fe3O4 MNPs (SPION) 
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and ZnSPION indicate good uniformity, with identical or very similar size of the core (Fig. S1). 
ICP‐OES analyses were carried out on the ZnSPION to obtain an unambiguous determination of 
the level of Zn2+ incorporation into the spinel structure. The yielded composition of the 
ZnSPION used in this study, obtained using a ratio of Zn/Fe precursors of 0.21, was Zn0.5Fe2.5O4. 
Thus, the applied synthetic methodology provided both excellent control of composition and 
particle size. 
To study the changes, elemental makeup and the oxidation states on the surface brought about by 
zinc doping, high‐resolution X-ray photoelectron spectroscopy (XPS) analyses were performed 
on the Fe 2p, Fe 3p, Zn 2p and O 1s regions of the Fe3O4 and Zn0.5Fe2.5O4 MNPs (Fig. S2). The 
XPS spectra of the Fe 2p region show all the characteristic features of iron oxides with a mixture 
of Fe2+ and Fe3+ present in their structures, such as a Fe 2p3/2 peak with a binding energy of 
710.60 eV and satellite shake-up peaks at higher binding energies (Fig. S2a).[54] The presence 
of Fe2+ and Fe3+ ions was confirmed through curve fitting of the Fe 3p peaks, which could be de-
convoluted into two sub-peaks at 55.6 eV and 53.9/54.0 eV assigned to Fe3+ and Fe2+ ions,[55] 
respectively for the SPION/ZnSPION (Fig. S2b). In the SPION the distribution between 
tetrahedral (A) and octahedral (B) sites is Fe2+ (B site):Fe3+ (A site):Fe3+ (B site) in a ratio of 
1:1:1. Several studies have shown that in these nonstoichiometric zinc-doped MNPs the Zn2+ 
ions are incorporated at the A sites but not exclusively – there is also substitution of Zn2+ into the 
octahedral sites in place of Fe 2+ (B site).[56] This appears to agree with the results of the present 
study. The XPS spectra of the Fe 3p peak could be fitted to a Fe3+/Fe2+ ratio of 2.2 and 3.5 for 
the Fe3O4 and Zn0.5Fe2.5O4  MNPs (Fig. S2b), respectively. These ratios are in good agreement 
with the structures of these nanomaterials in which a small proportion of Fe3O4 MNPs have been 
oxidized to Fe2O3. The higher Fe3+ content of the ZnSPION is consistent with Fe3+ by Zn2+ 
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substitution. For overall charge neutrality to be maintained, for every Fe3+ ion displaced by Zn2+, 
one Fe 2+ ion needs to oxidize to Fe3+  increasing the Fe3+/Fe2+ ratio.  The two peaks with binding 
energies of 1021.4 eV and of 1044.4 eV (Fig. S2c), can be attributed to Zn 2p3/2 and Zn 2p1/2, 
respectively.[57] Identification of the zinc oxidation state was possible by using the modified 
Auger parameter, α´, defined as the difference between the kinetic energies of the most intense 
photoelectron (2p3/2) and Auger (Zn L3M45M45) peaks plus the energy of the excitation source 
(1486.6 eV for Al  Kα). This calculation confirmed that zinc is in the 2+ oxidation state. The 
high-resolution XPS spectrum for the O 1s region showed a broad asymmetric curve, which can 
be de-convoluted into two well-defined peaks at binding energy of 532.1 and 530.1 eV (Fig. 
S2d). The peak at 530.1 eV is characteristic of the metal–oxygen–metal (M–O–M) lattice, whilst 
the peak at 532.1 eV has been reported to indicate the presence of other oxygen species (i.e., OH, 
H2O or carboxylate species) and/or defect sites with low oxygen coordination in ZnxFe3-
xO4 systems.[57]  
 
The motivation for doping magnetite NPs with Zn2+ ions was to improve the magnetic properties 
for biomedical applications. The magnetization (M) versus applied magnetic field (H) of the 
MNPs was measured at 5 K and 293 K (Fig. 1a,b). The MNPs exhibit superparamagnetic 
behavior without hysteresis and remanence at 293 K and ferromagnetic behavior with a 
coercivity (Hc, the applied field required to reverse magnetization direction) of 51 Oe (Fe3O4) 
and 178 Oe (Zn0.5Fe2.5O4) at 5 K. Most biomedical applications of MNPs benefit from high 
saturation magnetization (Ms) values. The Ms of the prepared SPION and ZnSPION is 55 emu g-1 
and 76 emu g-1 respectively at 293 K, among the highest for this particular MNP size. It has been 
shown that higher magnetization of this type of zinc-doped MNPs arises from the partial 
substitution of Fe3+ cations at A sites by non-magnetic atoms such as Zn2+, which results in an 
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enhancement of the net moment due to the reduced antiferromagnetic interaction between the 
Fe3+ ions at A and B sites.  Since this effect is seen to increase only up to a certain percentage of 
zinc (< 20 % of the total transition metal),[56] the prepared Zn0.5Fe2.5O4 ZnSPION can be 
considered of very high quality and optimum for enhanced MRI, where a high mass 
magnetization value typically leads to enhanced MRI sensitivity (vide infra).  
Stable and water soluble micelles with encapsulated Fe3O4 or Zn0.5Fe2.5O4 MNPs inside 
(mSPION or mZnSPION) were prepared by self-assembly of commercially available PEGylated 
phospholipids (1,2-dipalmitoyl-sn-glycero-3-phosphoetanolamine-N-[methoxy(polyethylene 
glycol)-2000) around the hydrophobic iron oxide NPs. Dynamic light scattering (DLS) studies 
show that mSPION and mZnSPION have very similar sizes with average hydrodynamic 
diameters below 50 nm (Fig. 1c and Fig. S3).   
To elucidate the extent to which the Zn-doped MNPs provide enhanced performance as MR 
imaging contrast agents compared to the magnetite NPs, we measured the longitudinal relaxation 
time (T1) and transverse relaxation time (T2) for mSPION and mZnSPION at 1.5 Tesla (T) on a 
Bruker Minispec relaxometer. The longitudinal relaxivity (r1) and transverse relaxivity (r2) 
values were determined by calculating the slope of a plot of the inverse relaxation time against 
the iron concentration. Consistent with the magnetization results, mZnSPION
 
showed the 
strongest MR contrast effect, with a relaxivity r2 value of 115.06 ± 17.46 mM−1 s−1, more than 3 
times larger than for mSPION (31.06 ± 5.39 mM−1 s−1).  
The contrast enhancement efficacy of the magnetic nanoconstructs was also tested in a 7 T pre-
clinical MRI scanner. The phantom images showed that the magnetic nanovaccine delivery 
vehicles are effective contrast agents under the settings for the preclinical in vivo imaging studies 
(vide infra), and that mZnSPION demonstrate superior performance (Fig. 1d). Moreover, both 
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mSPION and mZnSPION showed higher r2 at 7 T than at 1.5T, making them excellent contrast 
agents at higher field strengths.  
 
Fig. 1. Magnetic properties, MR relaxivities and MR imaging. Magnetization (M-H) curves of 
the prepared SPION and ZnSPION at: (a) 293 K and (b) 5 K (magnified view). (c) Summary of 
size and magnetic properties (longitudinal (r
1
) and transversal (r
2
) relaxivity values obtained at 
1.5 T). (d) T1 and T2-weighted phantom MR images of mSPION and mZnSPION dispersed in 2 
% agar obtained using a 7 T preclinical MR scanner with the determined relaxivity values. 
 
Double-functionalization of mZnSPION with polyIC and R837. It is emerging that some 
TLRs cooperate with each other to be more effective detecting imminent infection or danger and 
triggering protective immune responses, so we focused on the development of nanoconstructs 
carrying two TLR ligands as adjuvants. Recently, we reported that the TLR3 agonist polyIC can 
be incorporated non-covalently to mSPION to provide enhanced immune responses.[58] Since 
imidazoquinolines can intercalate into the double-stranded structure of nucleic acids,[59] we 
envisaged that using a polyIC coated mZnSPION would achieve co-delivery of polyIC and R837 
by complexing R837 molecules to polyIC. After overnight incubation of polyIC with 
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mZnSPION, the solutions were subjected to three cycles of ultrafiltration using a NanoSep 100k 
(MWCO 100 kDa) centrifugal device to remove unbound polyIC molecules. The mZnSPION-
polyIC showed the UV absorption peaks at 245 nm and 267 nm characteristic of poly (I:C) (data 
not shown). The amount of polyIC decorating the mZnSPION surface was quantified by 
measuring the absorbance at 260 nm after hydrolysis overnight with 0.2 N NaOH, 
ultracentrifugation (369,000 × g, 40 min) to remove the digested nanoparticles and comparison 
to a standard curve of polyIC treated in the same way.  
R837 presents fluorescence emission λmax at 338 and 354 nm using an excitation wavelength of 
250 nm. To elucidate if the imidazoquinoline molecules associate with polyIC the fluorescence 
spectra of R837 was recorded in the presence of increasing amounts of polyIC, showing 
significant fluorescence quenching like upon intercalation of other organic dye molecules into 
dsDNA (Fig. S4a). We reasoned that potentially, R837 could also be coordinated to unsaturated 
metal sites on the iron oxide surface. By alternating the order of addition of each TLR agonist, 
however, we found that the presence of the nucleic acid was critical for incorporating the 
imidazoquinoline molecules into the NP system. When R837 is added to the mZnSPION-polyIC 
complexes and excess R837 is removed by three cycles of ultrafiltration, the amount bound to 
the mZnSPION-polyIC complexes could be quantified analyzing a characteristic peak of R837 at 
320 nm by UV spectroscopy (Fig. S4b) and comparing with a calibration curve for R837. By 
contrast, when R837 was added first to the mZnSPION micelles and then polyIC, only the 
presence of polyIC could be detected (data not shown). Once the amount of R837 was estimated, 
solutions containing free R837 + polyIC (polyIC titrated into the solution of R837) were 
analyzed by UV-vis and compared against mZnSPION-polyIC-R837 – mZnSPION at the same 
iron concentration determined by ICP-OES to ensure that vaccines and nanovaccines had the 
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same amount of polyIC-R837 (Fig. S4c). The double functionalization with polyIC and R837 
increased the size of the micelles and led to the appearance of some aggregates, which were 
clearly detected both by DLS and TEM (Fig. S5a-c). As expected from the presence of the 
negatively charged polyIC molecules on the micelle surface, the zeta potential of the 
mZnSPION-polyIC-R837 was more negative than for the parent mZnSPION (- 20.2 ± 1.59 mV 
vs - 6.3 ± 0.95 mV) (Fig. S5d). To study the stability of the system and release of polyIC and 
R837, we measured the size and zeta potential of the prepared mZnSPION-polyIC-R837 
immediately after purification and one week later, in 10 mM PBS for size measurements and in 
NaCl 0.09 % for zeta potential. The size and negative zeta potential of the functionalized 
micelles did not change significantly, which is consistent with retention of polyIC on the surface 
of mZnSPION (Fig. S6). To study the release of R837, at designed time points 10 mM PBS 
solutions of mZnSPION-polyIC-R837 were subjected to ultrafiltration using a NanoSep 100k 
(MWCO 100 kDa) centrifugal device and the UV-vis spectra of the retentate and filtrate 
recovered from each device was measured to quantify the fraction of released R837. Analyzing 
the absorbance at 320 nm shows the release of R837 (Fig. S7).  
 
mZnSPION-polyIC-R837 complexes are effectively internalized and localize within the 
target endosomal compartments of antigen presenting cells. The uptake and fate of 
mZnSPION-polyIC-R837 complexes incorporating rhodamine B-modified DPPE phospholipid 
(< 5 %), was analyzed by fluorescence microscopy. LysoTracker Green was used to selectively 
stain late endosomes and lysosomes. Live cell microscopy studies showed that after 1 h 
incubation mZnSPION-polyIC-R837 complexes are co-localized with LysoTracker (Fig. S8a). 
This is an important result because it is widely accepted that TLR3 and TLR7 localize to and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
signal from acidified compartments of the endolysosomal pathway,[60] and studies have shown 
TLR7 to co-localize with TLR3-containing compartments.[61] Flow cytometry studies showed 
that the cellular uptake of mZnSPION-polyIC-R837 is quite fast, being taken up by macrophages 
even after 1 h exposure (Fig. S8b). 
 
Synergistic activation of antigen presenting cells and melanoma cell killing by polyIC-R837 
and mZnSPION-polyIC-R837. R837 and polyIC have both generated intense interest in cancer 
research owing to their potent antitumoural activities, which arise from diverse and cooperative 
mechanisms of action.[62,63] 
First, we investigated the immunostimulatory properties in the murine macrophage cell line 
J774A.1 and in bone marrow derived dendritic cells (BMDCs). We demonstrate a strong 
synergistic pro-inflammatory activation of the J774A.1 cells and of BMDCs over a range of 
polyIC and R837 concentrations and ratios (Fig. S9). However, secretion of cytokines by 
macrophages and DCs showed different sensitivity to stimulation with R837 and the polyIC-
R837 combination. Macrophages responded less to stimulation with R837 but strongly to the co-
stimulation (Fig. S9a). DCs became highly stimulated even with low R837 concentrations (0.5-5 
µg/mL) and showed less synergistic activation by co-stimulation with the TLR3 agonist (Fig. 
S9b).  
 
Next, BMDCs and J774A.1 macrophages were stimulated with the TLR agonists at fixed 
concentration, free and coating mZnSPION, singly and combined (Fig. 2). In macrophages, 
stimulation with polyIC-R837 and mZnSPION-polyIC-R837 synergistically enhanced IL-6 
production to a similar extent (Fig. 2a). In contrast, release of pro-inflammatory IL-6 and IL-12 
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cytokines by BMDCs was significantly increased after stimulation with mZnSPION-polyIC-
R837 complexes compared with the free TLR agonists (Fig. 2b). Although mZnSPION showed 
slightly higher toxicity than mSPION (Fig. 2c), the mZnSPION did not alter the viability of 
macrophages and BMDCs at the concentrations used for cell activation (iron concentrations < 
0.15 mM Fe). The enhanced activity of mZnSPION-polyIC-R837 compared to free polyIC-R837 
is also reflected in its cytotoxicity (Fig. 2d). To test whether delivery by mZnSPION also 
affected BMDC maturation, we analyzed the surface expression of co-stimulatory molecules and 
maturation receptors (CD80, CD86 and CCR7) (Fig. 2e). Increased expression of the co-
stimulatory molecules CD80 and CD86 is required for full activation of T-cells and induction of 
anti-tumour T-cell functions.[64] DCs co-stimulated with free polyIC and R837 and mZnSPION-
polyIC-R837 complexes showed comparable high expression levels of CD80 and CD86. 
Stimulation with uncoated mZnSPION resulted in baseline activation levels equal to those 
observed in untreated BMDCs. By contrast, the expression levels of the chemokine receptor 
CCR7 which regulates cell migration[65] was lower in BMDCs stimulated with mZnSPION-
polyIC-R837 complexes than in those stimulated with free polyIC-R837. Although the link 
between TLR signaling and zinc homeostasis has not been fully investigated, this result seems 
consistent with previous studies suggesting that increase in free zinc in DCs is involved in at 
least some DC maturation events and may affect the magnitude of adaptive immune 
responses.[66]  
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Fig. 2. mZnSPION-polyIC-R837 enhances immunostimulatory functions in macrophages and 
DCs compared to polyIC-R837. J774A.1 macrophages and BMDCs were incubated for 24 h with 
the indicated formulations. Cytokine release in (a) J774A.1 macrophages and (b) BMDCs. (c) 
Analysis of the cytotoxicity of mSPION and mZnSPION in J774A.1 macrophages. (d) Cell 
viability of J774A.1 macrophages and BMDCs. (e) Relative expression levels of maturation 
markers (CD80, CD86 and CCR7) expressed as the mean fluorescence intensity of each marker 
in BMDCs (CD11c+ MHC-II+ cells). Data are representative of three independent experiments. 
****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, ns = non significant by one-way ANOVA 
followed by Tukey’s test.  
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Although the primary target of the polyIC-R837 and mZnSPION-polyIC-R837 complexes are 
DCs, for which studying immunostimulatory functions is of special relevance, R837 and polyIC 
can exert additional effects against tumour cells.[62,67–69] To investigate the potential direct 
killing of the cancer cells, B16-F10(OVA) cells were incubated with different concentrations of 
polyIC, R837 and combinations of polyIC and R837 for 24 h, 48 h and 72 h. The results showed 
that only R837 has the ability to kill the B16-F10(OVA) melanoma cells. Moreover, the 
combinations of polyIC and R837 afforded cytotoxicity profiles comparable to those of R837 
alone (Fig. S10). These results suggest that ‘off-target’ R837 molecules interacting with B16-
F10(OVA) melanoma cells can potentially contribute to the overall antitumoural activity.  
Hence, this system unfolds as highly attractive for reinforcing antitumour responses through 
encounters with both immune cells and cancer cells. 
 
Immunization with polyIC-R837 drives effective immune responses which are enhanced by 
the mZnSPION and mSPION delivery vehicles. Clinical use of TLR agonists has been limited 
mainly by difficulties to restrict their systemic distribution and toxicity due to off-target 
activity.[34] To study the adjuvanticity, efficacy and in vivo effects of polyIC-R837, C57BL/6 
mice were immunized in the hind hock (lateral tarsal region just above the ankle) with low doses 
of these adjuvants (3 µg polyIC/mouse, 1 µg R837/mouse) free and complexed to mZnSPION (5 
µg mZnSPION/mouse). We observed minimal systemic production of IL-6 (Fig. 3a). By 
contrast, 24 h after immunization, both polyIC-R837 and mZnSPION-polyIC-R837 were able to 
activate DCs and NKs in the spleen and draining LNs (Fig. 3b, c). 
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Fig. 3. Innate immune responses triggered by low doses of polyIC-R837 and mZnSPION-
polyIC-R837 (3 µg polyIC, 1 µg R837 and 5 µg mZnSPION per mouse). (a) IL-6 levels in 
blood. (b) Relative mean fluorescence intensity histograms of CD69 natural killer cells (CD3- 
Nkp46+) maturation marker, extracted from inguinal and popliteal LNs and spleen of mice 24 
hours after immunization. (c) CD80, CD86, CD40 and CCR7 relative mean fluorescence 
intensity histograms of CD11c+ MHC-II+ dendritic cells extracted from inguinal and popliteal 
LNs and spleen of mice 24 hours after immunization. Data are mean ± SEM (n = 5 mice per 
group). ***P<0.001, **P<0.01, *P<0.05, ns = non-significant by one-way ANOVA followed by 
Tukey’s test. 
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Previously, we demonstrated that mSPION-OVA provides effective lymph node antigen delivery 
and significantly improves adaptive immune responses compared to administration of free 
OVA.[70] In the present study, we assessed the effect of co-administration of mZnSPION-
polyIC-R837 adjuvant and mSPION-OVA.  In these studies, mice were immunized twice (day 0 
and 14) with low doses of antigen (5 µg of OVA/mouse) and adjuvant (< 4 µg/mouse). The 
production of OVA-specific IgG, IgG1 and IgG2c antibodies in blood sera collected on days 0, 
14, 28 and 35 was evaluated by ELISA. On day 14, mice treated with mSPION-OVA and 
mZnSPION-polyIC-R837 already showed the highest levels of total IgG and IgG1 antibodies, 
and OVA-specific IgG2c titers increased by more than two log orders compared to mice treated 
with the nanoparticle-free vaccines (Fig. 4a). Thus, the polyIC-R837 adjuvant and OVA 
administered by the mZnSPION and mSPION vehicles elicited a more balanced Th1/Th2 
response enhancing both IgG1 and IgG2c titers. This is relevant since IgG2 antibody isotypes 
have been implicated in enhanced protection in both infectious diseases and cancer.[71]  
Moreover, the results showed that the combination of polyIC with R837 acts as a potent 
adjuvant, as the total IgG, IgG1 and, in particular, IgG2c titers were significantly increased with 
respect to vaccination with OVA alone (100 to 1000-fold) when OVA or mSPION-OVA were 
co-administered with polyIC-R837 or mZnSPION-polyIC-R837 complexes. In addition, 
compared with our recently developed mSPION-CpG adjuvant system,[70] which was tested 
under identical experimental conditions and significantly enhanced the adjuvanticity of CpG, 
immunization with polyIC-R837 (and even more so with mZnSPION) led to higher OVA-
specific antibody titers, further demonstrating the strong adjuvanticity of this specific 
combination of TLR agonists. 
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We also analyzed if the immunization with mZnSPION-polyIC-R837 and mSPION-OVA was 
able to drive antigen-specific CD8+ T-cell responses in mice, comparing the magnitude of this 
response against the simple mixtures (OVA + polyIC-R837). Each week we monitored the 
frequency of OVA257-264 (SIINFEKL)-specific CD8+ T-cells by H-2Kb/SIINFEKL dextramer 
staining and flow cytometric analysis.  After 7 days, mice immunized with mZnSPION-polyIC-
R837 and mSPION-OVA exhibited the highest frequency of circulating SIINFEKL-specific 
CD8+ T-cells in the blood (Fig. 4b). As can be expected, these levels were lower on day 14, but 
remained higher for the mice immunized with mZnSPION-polyIC-R837 and mSPION-OVA. On 
day 35 (experimental end point), the frequencies of circulating OVA-specific CD8+ T-cells in 
peripheral blood, spleen and draining LNs were similar for mice immunized with OVA + 
polyIC-R837 and  mSPION-OVA + mZnSPION-polyIC-R837 (Fig. 4c). Taken together, these 
results demonstrate that combination of polyIC and R837 is a robust and effective adjuvant 
inducing both cellular and humoral immune responses at very low doses following a prime-boost 
regimen. In addition, it avoids a strong and potentially harmful systemic inflammatory response, 
and its efficacy is significantly enhanced by the mZnSPION system. 
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Fig. 4. Immunization with mZnSPION-polyIC-R837 and mSPION-OVA enhances humoral and 
cellular immune responses. C57BL/6 mice were s.c. immunized into the flanks with the indicated 
formulations on day 0 (prime) and 14 (boost) (5 µg of OVA, 4 µg of polyIC, 0.5 µg of R837, 12 
µg mZnSPION and 45.5 µg SPION per mouse). (a) OVA-specific serum IgG1, IgG2c and total 
IgG titers. Analysis of frequency of circulating OVA257-264 (SIINFEKL)-specific CD8+ T-cells 
isolated from (b) blood at different time points and (c) blood, spleen and inguinal LNs at day 35 
after first immunization. Data presented as mean ± SEM. n = 5 mice per group. ****P<0.0001, 
***P<0.001, **P<0.01, *P<0.05, ns = non significant by (a) two-way ANOVA followed by 
Bonferroni’s test and (b, c) one-way ANOVA followed by Tukey’s test. 
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The efficacy of the vaccine against aggressive B16-F10(OVA) melanoma cells is enhanced 
using the mZnSPION and mSPION vehicles and by prevention of PD-L1/PD-1 T-cell 
inhibitory interactions. Considering the very encouraging development of potent cellular and 
humoral responses using small drug and nanoparticle doses, we next evaluated the efficacy of the 
vaccines and nanovaccines in the syngeneic melanoma model with the B16-F10 melanoma cells 
expressing OVA. This tumour model is highly aggressive and poorly immunogenic but 
susceptible to be recognized and killed by high avidity OVA257-264 (SIINFEKL)-specific CD8+ T-
cells.[72] Mice were s.c. immunized on days 0 and 14 with the different vaccines. On day 21, 
mice were challenged with 3 × 105 B16-F10(OVA) melanoma cells and tumour growth was 
monitored until the tumour volume reached the limits of the established endpoint (Fig. 5a). First, 
to determine the efficacy of the TLR3 and TLR7 agonist adjuvant combination, we compared 
immunization with OVA + polyIC, OVA + R837, OVA + polyIC-R837 and a control group that 
was immunized with 10 mM PBS. Compared to the PBS treatment, the immunization with each 
of TLR agonists combined with OVA significantly delayed the tumour growth (Figure 5b). 
Vaccination with OVA + polyIC-R837 significantly inhibited tumour growth and improved 
survival compared to immunization with tumour antigen and single TLR agonists at the same 
concentration (Fig. 5b-f). Strikingly, most mice immunized with OVA + polyIC-R837 remained 
free of visible tumour for several months post-tumour challenge despite the low doses of antigen 
and adjuvant administered (Fig. 5f). Next, we carried out studies to evaluate whether use of the 
nanoparticle vehicles (mZnSPION and mSPION) leads to improved anti-melanoma vaccination 
adopting a similar treatment schedule (Fig. 5g). The prophylactic effect of the vehicles alone was 
null. More than two months (70 days) after the last immunization mSPION-OVA combined with 
mZnSPION-polyIC-R837 achieved 100 % tumour rejection. Animals with a complete rejection 
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(CR) of tumour were given a second s.c. tumour cell challenge (3 × 105 B16-F10(OVA) cells) on 
the left back (contralateral to the first tumour inoculation), and tumour growth was monitored on 
both sides. All the mice rejected the tumour re-challenge. Thus, immunizations with and without 
nanoparticles showed remarkable tumour protection, with many animals (100 % in the case of 
immunization with mSPION-OVA + mZnSPION-polyIC-R837, and 60 % in the case of OVA + 
polyIC-R837 immunizations) tumour-free until the end of the experiment, 115 days after the 
boost (Fig. 5h, i). 
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Fig. 5. Effective protective immunity against B16-F10(OVA) melanoma cells by simple mixture 
of the TLR agonist adjuvant combination and antigen, without and with nanoparticles as delivery 
vehicles. (a) Treatment scheme. C57BL/6J mice (n = 5) were s.c. challenged with 3 × 105 B16-
F10(OVA) cells/mice seven days after the last vaccination with the indicated formulations (5 µg 
of OVA, 4 µg of polyIC and 2 µg of R837 per mouse). (b-f) Average and individual tumour 
growth curves and Kaplan–Meier survival curves. (g) Treatment scheme. C57BL/6J mice (n = 5) 
were s.c. challenged with 3 × 105 B16-F10(OVA) cells/mice seven days and seventy days after 
the last vaccination with the indicated formulations (vaccines and vehicles: 5 µg of OVA, 12 µg 
of polyIC, 3.5 µg of R837, 10 µg mZnSPION and 55 µg mSPION; nanovaccines: mZnSPION(10 
µg)-polyIC(8 µg)-R837(2.5 µg), mSPION(55 µg)-OVA(5 µg)). (i, h) Tumour growth and 
Kaplan–Meier survival curves. CR = fraction of complete tumour rejection. 
To analyze the magnitude and quality of the memory response generated in the mice that 
survived free of disease until the end of the experiment (day 129), the CD8+ T cell population in 
the spleen was analyzed. Remarkably, antigen-specific T-cells elicited by the polyIC-R837-
containing vaccines persisted even 115 days after the boost. The T cell memory compartment 
can be subdivided into two populations, central memory CD8+ T cells (Tcm) and effector memory 
(Tem).[73] The frequency of Tem and Tcm population was similar in the mice immunized with and 
without nanoparticle delivery vehicles (Fig. S11a). However, analysis of the Tem subset revealed 
that immunization with mZnSPION-polyIC-R837 + mSPION-OVA leads to an increased 
population of SIINFEKL-specific Tem compared to mice immunized with polyIC + R837 + OVA 
(Fig. S11b). To evaluate the quality of CD8+ T cell responses, cellular extracts from spleen were 
cultured ex vivo and incubated with the antigenic peptide SIINFEKL for 5 h, and the IFN-γ and 
TNF-α intracellular production, as well as the degranulation marker CD107a, were analyzed by 
flow cytometry. The data demonstrated that mice immunized with the nanoparticles generate T 
lymphocytes with enhanced cytolytic activity (Fig. S11c,d).  Taken together, these results 
indicate development of a potent and long lasting antitumor immunity, in which the NPs improve 
both the magnitude and the quality of the memory response. 
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Novel therapeutics targeting immune checkpoints have fueled considerable excitement in cancer 
treatment.[74] To date, the most effective immune checkpoint inhibitors are monoclonal 
antibodies that bind to either PD-1 or PD-L1.[75] The B16-F10(OVA) melanoma model used in 
our in vivo functional experiments showed a high PD-L1 basal expression (Fig. S12), thus 
indicating that this tumour model is susceptible to be rejected by PD-L1 checkpoint blockade-
based treatments. Hence, we next evaluated the potential to improve the therapeutic efficacy by a 
combination therapy which prevents PD-L1/PD-1 T-cell inhibitory interactions.  
However, there are several limitations in the use of PD-L1 blocking antibodies. The short 
duration of the induced responses requires successive antibody administrations for the treatment 
to be effective. Moreover PD-L1, is expressed on a variety of immune cellular populations, 
including T- and B-lymphocytes, dendritic cells, macrophages, mesenchymal stem cells, natural 
killer cells and bone marrow-derived mast cells,[76],[77] where blockade can result in 
uncontrolled auto-reactivity and significant toxicity. To overcome these limitations, we have 
developed a genetically modified B16-F10(OVA) cell line with a downregulated expression of 
PD-L1 through the CRISPR/Cas9 gene editing system delivered within lentiviral particles (Fig. 
S12).[78] This novel technology allows the permanent disruption of the target gene based 
uniquely on two components: a short sequence of complementary RNA to guide the recognition 
of the target gene and the enzyme caspase 9 for targeted DNA cleavage.[79] The use of 
lentivirus for its delivery enables to diminish the detrimental effects arising from the sustained 
expression of caspase 9.[80] Lentivirus were produced in 293T cells and purified to use them as 
a tool for the targeted disruption of the PD-L1 gene in B16-F10(OVA) cells in vitro.  
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This genetically modified cell line, B16-F10(OVA) ∆PD-L1, was used in a prophylactic 
immunization assay (Fig. S13). As expected, the permanent PD-L1 checkpoint blockade 
enhanced the efficacy of vaccination with OVA + polyIC-R837, with now 100 % of the animals 
free of tumour at the end of the experiment (115 days after the last immunization).   
Finally, we carried out a preliminary study to evaluate this system in the setting of therapeutic 
vaccination. For this, C57BL/6 mice inoculated subcutaneously with 3 × 105 B16-F10(OVA)  
cells were vaccinated with OVA and polyIC-R837 free or in conjugation with the magnetic 
micelles on days 4, 7 and 11 and tumour growth was measured for 18 days. To compare the 
adjuvant effects of polyIC-R837 and nanoparticle vehicles another group of mice was treated 
with mZnSPION and mSPION-OVA. Results showed significant tumour growth inhibition with 
all three treatments. Notably, OVA + polyIC-R837 free and mZnSPION + mSPION-OVA 
provided comparable tumour growth inhibition, which further demonstrates the strong adjuvant 
effects of the nanoparticles. Treatment with mZnSPION-polyIC-R837 and mSPION-OVA 
provided the most potent tumour growth inhibition (Fig. 6). However, one week after the last 
treatment tumour necrosis and early ulceration signs were detected in some mice, and therefore 
studies to tackle control of the established tumours by multi-modal approaches are underway. 
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Fig. 6. mZnSPION-polyIC-R837 delays the tumour growth enhancing the efficacy of the free 
ligands. (a) Treatment scheme. C57BL/6J (n = 5) mice were s.c. challenged with 3 x 105 B16-
F10(OVA cells/mice. At days 4, 7 and 11 mice were treated with TLR agonist and OVA in 
solution or attached to nanoparticles. (b) Curves of tumour growth, (c) animal weight over the 
treatment schedule, and (d) tumour volumes 15 days after the inoculation of B16-F10(OVA) 
cells. Arrows indicate the days of therapy administration. Doses: 5 µg of OVA, 8 or 12 µg of 
polyIC, 2 µg of R837; nanovaccines: 5 µg of OVA, 8 µg of polyIC, 2 µg of R837, 27 µg 
mSPION, 10 µg mZnSPION. 
 
Detection of different migration of nanovaccine components to tumour and draining LNs 
combining MR and SPECT/CT imaging. Finally, given the excellent antitumour results 
obtained in response to immunization with mZnSPION-polyIC-R837 and mSPION-OVA, we 
studied their migration from the s.c. site of injection combining MR and SPECT/CT imaging in 
B16-F10(OVA) tumour bearing mice. The relaxometric studies showed that mZnSPION 
provides 3-4 times better sensitivity as T2 contrast agent than the mSPION, and therefore are 
more suitable for MRI tracking at the low concentrations used in the immunization studies. To 
investigate the potential of tracking by MRI the migration of mZnSPION-polyIC-R837 from the 
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injection site to draining LNs and tumour, the B16-F10(OVA) melanoma cells were implanted 
into C57BL/6 mice, and after tumour establishment, mZnSPION-polyIC-R837 (100 µL, [Fe] = 6 
mM) was injected into the peritumoural region. MR images were acquired prior to the 
administration of mZnSPION-polyIC-R837 and 24 h and 48 h post-injection. Despite greatly 
enhanced magnetic properties, we could not detect darker signals due to migration and reduction 
in T2 values in the tumour or draining LN (right inguinal LN, Fig. 7a). Instead, MRI showed that 
both 24 h and 48 h post-injection the mZnSPION-polyIC-R837 remained mainly at the injection 
site (Fig. 7c). To investigate if the polyIC-R837 coating affects the migration kinetics of the 
delivery vehicles, a group of mice were administered the “naked” mZnSPION. Notably, 
administration of “naked” mZnSPION results in reduction of T2 values in the draining LNs 24 h 
post-injection (Fig. 7b).  
Due to sensitivity limitations of MR imaging, we radiolabelled the nanovaccines with 67Ga for 
SPECT/CT imaging. We previously demonstrated effective 67Ga radiolabeling of “naked” 
mSPION.[70] Here, we demonstrate that zinc doping and biofunctionalization with polyIC-R837 
or OVA does not affect the efficiency of radiolabeling protocol (Fig. S14a). We assessed the 
stability of the 67Ga-labelled mZnSPION-polyIC-R837 by quantifying 67Ga release in PBS at 37 
ºC. The studies showed good stability, with less than 12 % of the bound 67Ga being released over 
24 h in the presence of a large excess of DOTA chelator (at DOTA:NP molar ratio of 1 × 106:1). 
The radiolabelled mSPION-OVA system showed comparable stability (Fig. S14b). The 
radiolabeling stability analysis confirmed that the nanoparticles were stable when challenged, 
and therefore suitable for in vivo tracking of both nanovaccine components.  
Consistent with the MRI studies, SPECT/CT images and ex vivo analysis of mice injected with 
67Ga-labelled mZnSPION-polyIC-R837 (Fig. 7d-g) showed that the particles remain mostly at 
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the injection site (Fig. 7d). However, the quantitative analysis of the radioactivity accumulation 
in different organs revealed that 24 h post-injection, some migration had occurred to the tumour 
and to the inguinal and axillary LNs (0.02-0.375 % of the injected dose, Fig. 7g).  
 
Notably, 67Ga-labelled mSPION-OVA system migrated faster showing clear accumulation in 
draining LNs and in LNs distant from the injection site already 3 h post-injection. mSPION-
OVA was also detected in the tumour at 24 h and 48 h (Fig. 8). Moreover, even when the 67Ga-
labelled mSPION-OVA was injected into the left hind hock of mice, the accumulation of 67Ga-
labelled mSPION-OVA in LNs and tumour is higher than for peritumourally injected 67Ga-
labelled mZnSPION-polyIC-R837 (Fig. S15 and Fig. 7). A similar migration pattern was found 
in tumour-free mice (Fig. S16). 
Overall, combination of MRI and SPECT/CT imaging reveals differences in the migration 
capacity of the nanovaccine components. In the case of mSPION-OVA a higher proportion of 
nanoparticles can enter directly the lymph to provide higher accumulation in LNs and tumour 
within the first hours of administration, whereas the mZnSPION-polyIC-R837 system is 
effective at creating a depot at the site of injection from which the adjuvant nanoparticles can 
migrate more slowly to draining LNs and tumour. In this way we propose that the nanoparticles 
allow antigen to be processed quickly to initiate T-cell priming events within the first hours of 
administration and are able to sustain the responses over longer periods. The slow release of pro-
inflammatory stimuli by mZnSPION-polyIC-R837 provides a way to enhance endocytic antigen 
uptake by DCs in the skin, initially leading to loss of DC motility as shown by the 
downregulation of CCR7 (Fig. 2e). This can be followed by a characteristic maturation period 
whereby the slow moving wave of DCs regain their mobility and undergo a switch of 
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the chemokine receptor repertoire and upregulation of their antigen presentation machinery, 
eventually migrating to LNs to induce full-fledged effector responses.[50] 
 
 
Fig. 7. In vivo tracking of mZnSPION(-polyIC-R837). T2-weighted MR imaging at 7T (a-c). (a) 
Quantitative analysis of T2-weighted images in the right inguinal lymph node and tumour before 
and 24 h after s.c. injection of mZnSPION-polyIC-R837 into the peritumoural region (100 mL, 
[Fe] = 6 mM). (b) Differences in T2 in the inguinal lymph node of mice administered mZnSPION 
or mZnSPION-polyIC-R837. (c) T2-weighted images of B16-F10(OVA) tumour bearing mice 
before and at different time points after s.c. injection of mZnSPION-polyIC-R837 (T, tumour; ♦, 
injected sample). SPECT/CT images and ex vivo analysis of mice injected with 67Ga labelled 
mZnSPION-polyIC-R837. Tumour bearing mice were injected with radiolabelled micelles into 
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the peritumoural region (d-g) (5.73 µg of ZnSPION, 19.1 MBq). (d) In vivo SPECT/CT images 
taken 3 h post-injection. Ex vivo analysis of the biodistribution after 24 h. (e) Photograph of 
selected harvested organs, (f) SPECT/CT image of the harvested organs and (g) biodistribution 
expressed as percent injected dose per organ. I, injected sample; T, tumour; bLN, brachial LN; 
aLN, axillary LN; Lu, lungs; L, liver; S, spleen; K, kidneys; iLN, iliac LN; sLN, sciatic LN; 
inLN, inguinal LN; pLN, popliteal LN. Data presented as mean ± SEM. n = 2-5 mice per group. 
*P<0.05 by t test (unpaired). 
 
Fig. 8. SPECT/CT images of melanoma tumour bearing mice after s.c. injection of 
67
Ga labelled 
mSPION-OVA (20.7 µg of SPION, 41.0 MBq) into the flank. (a, d) 3 h, (b, e) 24 h and (c, f) 48 h 
post-injection. (a-c) dorsal and (d-f) lateral views of in vivo images at different time points are 
shown. (g, h) SPECT/CT image of the harvested organs and biodistribution expressed as percent 
injected dose per organ. I, injected sample; T, tumour; bLN, brachial LN; aLN, axillary LN; Lu, 
lungs; L, liver; S, spleen; K, kidneys; iLN, iliac LN; sLN, sciatic LN; inLN, inguinal LN; pLN, 
popliteal LN.  
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Discussion 
TLR agonists, by activating a broad range of innate immune cells and directly killing different 
types of cancer cells including melanoma cells, offer unique mechanisms of maximizing anti-
tumour immunity. However, high doses are often required to elicit a strong enough response, 
leading to unacceptable toxicity. Studies have shown that scientifically rational combinations of 
TLR agonists can synergistically activate immune responses,[38,39,81] offering the potential to 
achieve strong antitumour immune responses using much lower doses. There is growing 
evidence that in targeted delivery of TLR agonists and tumour antigen both nano and 
microparticle-based systems can provide enhanced antitumour immunity compared to the free 
drugs.[8,16,51,82,83] This suggests that optimizing the anti-cancer efficacy of TLR-targeted 
therapeutics may require using delivery systems that promote and combine different ways of 
interaction with antigen presenting cells at both the site of injection and target tissue, exploiting 
the dynamic nature of nanoparticles in vivo (e.g. initial size, biofunctionalisation, aggregation, 
etc.). However, this aspect has not been investigated so far. Our data demonstrate that the 
combination of polyIC and imiquimod synergizes to create a potent adjuvant for the 
development of effective antitumour vaccines, eliciting robust T-cell and antibody responses to 
tumour antigen at low doses and avoiding systemic adjuvant toxicity and morbidity. We have 
shown that the antitumour immune responses generated with this combination of TLR agonists 
co-administered with tumour antigen can be significantly enhanced by targeted delivery using 
micelles filled with 5 nm MNPs, which help to regulate the trafficking and processing of antigen 
and adjuvant by antigen presenting cells, and by PD-L1/PD-1 immune checkpoint inhibition. We 
optimized the magnetic properties of the MNPs by controlled zinc(II) doping, and carried out 
organic chemistry-free radiolabeling with 67Ga for enhancing in vivo multimodal imaging (MRI 
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+ SPECT/CT) tracking, allowing detection of differences in MNP migration from the 
subcutaneous site of injection to draining LNs and tumour due to differences in size and 
biofunctionalisation.  
TLR agonists have been extensively investigated for vaccine formulations with promising 
results. However, they have been used mainly acting singly and as a monotherapy, limiting their 
efficacy and giving rise to systemic toxicity. Among these drugs those targeting endosomally 
localized TLR3, TLR9 and TLR7/8 are ideal candidates for benefiting from nanoparticle 
delivery. Herein, we investigated the effect of co-activation of TLR3 and TLR7 using polyIC and 
imiquimod, respectively; two drugs with demonstrated antitumour efficacy when used as single 
drugs and with considerable potential to complement and/or synergize in their antitumour 
functions due to their known mechanisms of action. Thus, all TLRs signal through the myeloid 
differentiation primary response protein 88 (MyD88)-dependent pathway, except TLR3 that 
primarily uses the toll/interleukin-1 receptor domain-containing adapter-inducing interferon-β 
(TRIF)-dependent pathway.[84] Moreover, polyIC is not only a TLR3 ligand but also a MDA5 
agonist.[85] This makes polyIC of great interest as a potential anti-cancer agent. TLR3 and 
MDA5 are expressed both by immune cells and by cancer cells and studies have demonstrated 
distinct yet complementary roles for MDA5 and TLR3 in polyIC-mediated activation of DCs and 
NK cells and pro-apoptotic activity against tumour cells, leading to profound antitumoural 
effects in different tumours. The main antitumoural activity of imiquimod is driven by TLR7-
mediated induction of pro-inflammatory cytokines, chemokines and other mediators by DCs to 
induce a profound T-helper (Th1)-weighted antitumoural cellular immune response.[62] 
However, several studies have shown that imiquimod enhances also antigen-specific activation 
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of antitumoural T-cells,[86–90] antibody production by B cells,[91–94] activates NK cells and 
exerts Bcl-2- and caspase-dependent pro-apoptotic activity against some tumour cells. [95–97]   
Our data confirm that combinations of polyIC and R837 provide synergistic activation of 
macrophages and dendritic cells, which show different sensitivity to each individually and when 
combined, and that R837 could directly kill the target melanoma cells. Indeed, this has made 
imiquimod useful for melanoma treatment,[98,99] while other studies showed that not every 
cancer cell line can be killed by polyIC.[67]  However, the polyIC-R837 complexes in small 
doses enabled generation of strong immune activation at lymphoid tissue without inducing 
potentially toxic systemic cytokine release. We evaluated the effectiveness of vaccination with 
and without nanoparticle vehicles on the induction of antitumour immunity in an aggressive and 
poorly immunogenic mouse melanoma model using B16-F10 melanoma cells expressing OVA 
and the immune inhibitory transmembrane protein PD-L1. It has been shown that an optimal 
anti-cancer treatment regime for the TLR7 agonist R848 (resiquimod) requires the possibility for 
sustained stimulation, which was achieved using cycles of repeated R848 injection.[100] Here, 
instead we used the slow migration of the mZnSPION-polyIC-R837 system from the s.c. 
injection site to LNs and tumour to achieve the sustained activation of APCs. On the other hand, 
it is known that a low antigen dose is required to generate the high-avidity T-cells that provide 
more potent responses against tumours and pathogens, but it has been proven difficult to induce 
these T-cells through vaccination.[101,102] Several authors have reported efficacy of anti-
tumour prophylactic and/or therapeutic vaccines with reduced antigen doses in the range of 10-
100 µg/mouse.[12,103–109]  Here, we demonstrate the combined effect of using polyIC-R837 as 
potent adjuvant and mSPION for OVA delivery. Mice immunized with 5 µg of OVA and 
polyIC-R837 delivered by the MNP-filled micelles developed long term protection against the 
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melanoma cells with 100 % of nanoparticle-immunized mice rejecting tumour re-challenge 70 
days after the last immunization, which is consistent with a strong memory effect.   
Another paradigm in immunology is that kinetics of antigen and DC migration are key 
parameters with regard to T-cell and anti-tumour responses, adaptive immunity and 
tolerance.[48,110] The data presented here extend recent findings on nanoparticle delivery of 
TLR agonists to an effective combination of TLR agonists. In the context of TLR agonist and 
antigen delivery, it may be important to consider the different migration and dynamic 
aggregation of the nanoparticles in vivo. Currently it is not known which type of particles are 
preferred for generating the most effective antitumour immunity, namely, those that are small 
and passively traffic to LNs or those that by being larger can exploit uptake by DCs in the 
periphery to reach the LNs, or whether the best results are obtained by specific combinations of 
the two. The mZnSPION-polyIC-R837 system displayed more tendency to aggregate, and by 
combination of MRI and SPECT/CT imaging we showed that are retained longer at the site of 
injection with a small percentage of particles reaching the draining LNs. On the other hand, the 
mSPION-OVA system aggregated less, migrated faster from the injection site and provided 
higher accumulation in the LNs at least until 48 h post-injection.  
Although checkpoint inhibitors are an important breakthrough, this therapy does not show any 
clinical benefit in most patients (70%-80%), and thus now the focus is on combination 
immunotherapy approaches [111],[112] It has been recently shown that combined administration 
of poly-IC and anti-PD-L1 mAb into tumour-bearing mice is able to generate potent immune 
responses resulting in the complete eradication or remarkable reduction of tumour growth.[113] 
The study suggested that this type of combination immunotherapy treatment would work even in 
cases where no reliable tumour associated antigens capable of eliciting effective antitumour T-
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cell responses have been identified. However, PD-L1/PD-1 blockade therapy in B16 and in 
C57BL/6 is very inefficacious and it only works in combination therapies.[114] We explored the 
potential of a combination treatment bringing immunization with OVA + polyIC-R837 together 
with the B16-F10(OVA) melanoma cell with silenced PD-L1. PD-L1 blockade achieves the 
same effects than knocking out PD-L1 in cancer cells as demonstrated previously.[78] However, 
while administration of blocking antibodies may have uncontrolled systemic effects, here we 
focused on the specific effects over cancer cells without affecting other factors such as antigen 
presentation in peripheral tissue. Directly evaluating the relative roles of PD-L1 expression by 
the tumour and host cells in the suppression of anti-tumour immune responses is emerging as a 
central and controversial unknown to be able to understand and predict the therapeutic benefit 
from antibodies interfering with PD-L1 activity.[115] Although it should be of no surprise that 
we observed enhanced protection against the tumour challenge with 100 % rate of response to 
the treatment, even for the nanoparticle-free vaccines, it is an important result. It provides 
support for the combinatorial immunotherapy approach using the checkpoint inhibitors and 
potentially quick clinical translation. Hence, the immunotherapy treatment described here uses 
drugs that are already used clinically or are currently undergoing clinical testing.   
Many nanosystems used for application in cancer are difficult to synthesize. The preparation of 
mZnSPION-polyIC-R837 is fully by self-assembly, mimicking the formation of liposomal 
formulations. This provides a further framework for future clinical translation. Moreover, while 
the present work shows effective long term protection against a syngeneic aggressive melanoma 
challenge with a simple system, this system offers the possibility for tackling control of 
established tumours by multi-pronged strategies that exploit further the magnetic properties of 
the delivery vehicles (e.g. hyperthermia, magnetically guided drug delivery), and/or are 
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combined with other immunotherapy approaches, radiation therapy and chemotherapy known to 
delay tumour growth and synergize with anti-cancer vaccines. 
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Materials and methods 
Synthesis and characterization of SPION and ZnSPION. The hydrophobic magnetic 
nanoparticles, (SPION and ZnSPION ((ZnxFe1-x)Fe2O4; x ≤ 0.5)) were prepared adopting 
previously described precedures.[116,117] The size of the MNPs was determined by 
transmission electron microscopy (TEM) on a JEOL JEM-2011 electron microscope operating at 
200kV. The samples were prepared by depositing a drop of MNPs onto a copper specimen grid 
coated with a holey carbon film (Electron Microscopy Sciences). Samples were prepared by 
dissolving 1 mg of nanoparticles in THF to a final concentration of 0.1 mg/mL. At least 300 
particles were measured using the Image J software to determine MNP size. The Fe and Zn 
concentration in the samples was determined by ICP-OES analysis carried out by the SGIker 
analytical facility of the University of the Basque Country (UPV/EHU; Leioa, Spain). ICP-OES 
was carried out using a Perkin Elmer Optima 5300 DV, employing an RF forward power of 1400 
W, with argon gas flows of 15, 0.2 and 0.75 L/min for plasma, auxiliary and nebulizer flows, 
respectively. Using a peristaltic pump, sample solutions were taken up into a Gen Tip cross-Flow 
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nebulizer and Scotts spray chamber at a rate of 1.50 mL/min. The instrument was operated in 
axial mode. The selected wavelengths (238.024, 239.562, 259.939 nm) were analyzed in fully 
quant mode (three points per unit wavelength). A range of calibration standards were prepared 
using single element 1000 mg/L stock solutions (Fisher Scientific UK LTD) and a Merck multi 
element standard (ICP Multi element standard solution VI CertiPUR®, Merk) was employed as a 
reference standard. XPS experiments were performed in a SPECS Sage HR 100 spectrometer 
with a non-monochromatic X-ray source (aluminum Kα line of 1486.6 eV energy and 350 W). 
The samples were placed perpendicular to the analyzer axis and calibrated using the 3d5/2 line of 
Ag with a full width at half maximum (FWHM) of 1.1 eV. The selected resolution for the spectra 
was 10 eV of Pass Energy and 0.15 eV/step. Measurements were made in an ultra high vacuum 
(UHV) chamber at a pressure below 8·10-8 mbar. Magnetic measurements were carried out in a 
7T SQUID magnetometer at the Magnetic Measurements Service of the University of the Basque 
Country (UPV/EHU; Leioa, Spain).  
Synthesis and characterization of mZnSPION(-polyIC-R837) and mSPION(-OVA). 
mSPION, mSPION-OVA and rhodamine-labelled micelles were prepared as described 
previously.[58,70,118] For the synthesis of mZnSPION, different ZnSPION-to-lipid ratios were 
used to optimize the micelling process and the properties (e.g. size). The reported results were 
obtained with micelles prepared with a oleic acid-coated ZnSPION:DPPE-mPEG(2000) weight 
ratio of 1:5. The micelle size and zeta potential analysis was measured with a NanoSizer 
(Malvern Nano-Zs, UK). For size measurements samples were diluted in water, and for zeta-
potential measurements in nanopure water with NaCl 0.09 %. The results are a mean of at least 
three measurements matching quality criteria. Relaxivity measurements were carried out at 37 ⁰C 
on a Bruker Minispec mq60 instrument operating at 1.47 T. T1 and T2 values were measured for 
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each sample at different Fe concentrations using inversion-recovery and CPMG methods 
respectively. The relaxivity values, r1 and r2, were calculated through linear least squares fitting 
of 1/relaxation time (s-1) versus the iron concentration ([Fe] mM). The MRI phantom 
experiments were carried out on a Bruker Biospec 7 T with a 12 cm gradient capable of 
delivering 400 mT/m using a 40 mm volume coil. T2-weighted images were acquired by using 
Bruker's MSME (Multi slice Spin echo) sequence. The echo time (TE) values were varied in 128 
steps ranging from 10 ms to 1280 ms and a repetition time (TR) of 15 s. T1 maps were obtained 
by using a spin echo sequence. Images were acquired at ten different TR values 150, 500, 1000, 
1500, 2200, 3000, 4000, 5200, 7.600, 17500 ms). All data were acquired with: 256 x 256 points 
and a Field of View of 3 cm x 3 cm, slice thickness of 1.5 mm, no gap between slices and one 
average. The T1 and T2 map images were calculated using the Bruker's Paravision 5.1 software 
via the Levenberg‐Margardt method. 
For biofunctionalisation with the TLR agonists, lyophilized polyIC and imiquimod (Invivogen) 
were resuspended in endotoxin-free water to a final concentration of 1000 µg/mL and 500 
µg/mL, respectively. Double-functionalized MNPs were prepared through a two-step process. 
The mZnSPION solution (500 nM of nanoparticle) was mixed with the poly(I:C) solution (156 
µg/mL) and the mixture was stirred overnight at 700 rpm at room temperature. The unbound 
poly(I:C) were removed with three cycles (1500 × g, 5 min) of ultrafiltration with NanoSep 100k 
(MWCO 100 kDa) centrifugal devices (Pall Life Sciences).Then, the formed mZnSPION-polyIC 
micelles were resuspended in imiquimod solution (250 µg/mL), keeping the final volume 
constant. These mixtures were stirred and purified as described for the polyIC adjuvant. The final 
pellet was resuspended in the same initial volume of nanopure water or 10 mM PBS and stored 
at 4 °C. The quantification of bound imiquimod was performed by UV-visible spectroscopy 
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analyzing the absorbance at 320 nm, respectively, and comparing with a calibration curve for 
imiquimod. Once the amount of R837 was estimated solutions containing free polyIC + R837 
(polyIC titrated into the solution of R837) were analyzed by UV-vis and compared against 
mZnSPION-polyIC-R837 – mZnSPION at the same iron concentration determined by ICP-OES 
to ensure that vaccines and nanovaccines had the same amount of polyIC-R837. Release 
experiments were carried out incubating the mZnSPION-pIC-R837 sample in 10 mM PBS under 
continuous stirring. Released drugs were analyzed by UV absorption spectroscopy after 
ultrafiltration with NanoSep 100k (MWCO 100 kDa) centrifugal devices. UV absorption spectra 
were acquired using a NanoDrop ND 1000 (version 3.5.2) Spectrophotometer (NanoDrop 
Technologies). Fluorescence experiments to assess the interaction of imiquimod with polyIC 
were conducted in a Fluoromiter Fluorolog-TSPC (Horiba-Jovine Ivone) by irradiating the 
samples with an excitation wavelength of 250 nm. TEM images, ICP-OES analysis and DLS 
measurements of the (biofunctionalised) samples were acquired as described above for the 
“naked” MNP-filled micelles. 
Localization of intracellular micelles by confocal microscopy and flow cytometry. The 
J774.A1 murine macrophage cell line was purchased from the ATCC and cultured in DMEM 
supplemented with 10 % FBS, 1 % L-glutamine (all from Gibco, Life Technologies) and 1 % 
penicillin-streptomycin (P/S; Sigma Aldrich), and maintained in a humid atmosphere at 37 °C 
and 5 % CO2. For confocal microscopy imaging, the J744.A1 cells were seeded in poly-lysine-
coated 35 mm glass bottom dishes (MatTek) in 2 mL of complete DMEM medium. Then, cells 
were incubated for 1 h at 37 ºC and 5 % CO2 in media containing rhodamine-labelled 
mZnSPION-polyIC-R837 (25 nM of nanoparticle), 1 µM LysoTracker Green DND-26 
(Invitrogen) and 3 drops of NucRed® Live 647 ReadyProbes® Reagent (Life Technologies). All 
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images were acquired on a Zeiss LSM 510 META confocal microscope equipped with 63X 
magnification oil lens. Fluorescence images were taken in sequential mode at the excitation 
wavelengths of 488 nm, 561 nm and 633 nm for LysoTracker Green DND-26, rhodamine B or 
NucRed® Live 647 ReadyProbes® Reagent, respectively. The thickness of each optical slice 
was set at 3 µm for each color channel. Transmitted light images were also acquired. Image 
analysis was performed using the software Zeiss LSM Image Browser. In the case of uptake 
studies by flow cytometry, J774.A1 cells were plated in 96-well plates (1 × 105 cells/well) and 
allowed to adhere overnight in DMEM medium supplemented as described before. Fluorescent 
MNPs were diluted in medium and added to cells, which were maintained at 37 °C, 5% CO2 
during 1 h, 3 h or 24 h. Then, the medium was removed and cells were transferred to cytometer 
tubes by gentle pipetting in sterile PBS and pellet down by centrifugation (580 x g, 5 min, 4 °C). 
Cells were resuspended in a final volume of 200 µL of FACS buffer (1% BSA in 10 mM PBS). 
Rhodamine uptake was measured using a FACS Canto II flow cytometer (BD bioscience) and 
the data were analysed using the FlowJo, LCC software. J774A.1 cells were electronically gated 
based on the forward and side scatter parameters and the not-single events left out based on 
forward area and height scatter parameters. Rhodamine signal coming from the MNPs-filled 
micelles was analysed within this population. 
Cytotoxicity and cytokine production studies. To assess cytokine production at 24 h, J774.A1 
cells were seeded at 2.5 ×104 cells/well (100 µL per well) in flat bottom 96-well plates and 
allowed to adhere overnight. Then, medium was removed and cells were left untreated or treated 
with the immunostimulatory formulations and the corresponding controls, diluted accordingly in 
medium, in triplicate. After 24 h, cell supernatant was removed and frozen for subsequent 
cytokine analysis and cytotoxicity assay (vide infra). The B16-F10(OVA) murine skin melanoma 
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cell line stably transfected with a plasmid responsible of the expression of OVA was kindly 
gifted by the group of Dr. Pablo Sarobe (Center of Applied Medical Research, CIMA, Pamplona, 
Spain). These cells were cultured in RPMI-1640 (Lonza) supplemented with 10 % FBS, 1 % L-
glutamine and 1 % P/S, and maintained in a humid atmosphere at 37 °C and 5 % CO2. To assess 
cell viability at 24 h, 48 h and 72 h, cells were seeded at 7 × 103, 2.5 × 103 and 1.5 × 103 
cells/well (100 µL/well), respectively, in flat bottom 96-well plates and allowed to adhere 
overnight. Media was removed from each well prior to adding 100 µL of each sample, properly 
diluted in cell culture media, per well and in triplicate. To determine cell viability, 100 µL/well 
of MTT reagent (Roche) diluted in media to a final concentration of 0.25 mg/mL was added after 
removal of the supernatant. After 1 h incubation at 37 °C, the reagent was removed and 200 
µL/well of DMSO were added to solubilize formazan crystals. Finally the optical density of the 
samples was measured in a TECAN Genios Pro 96/384 microplate reader at 550 nm and data 
was represented as the percentage of cell survival compared to control wells.  
BMDC maturation assay. BMDCs were prepared as described previously.[70] The various 
immunostimulatory formulations (100 µL per well, appropriately diluted in complete RPMI-
1640) were added to the DC containing wells (2 × 105 cells per well in 96-well plates) and 
incubated for 24 h in a humid atmosphere at 37 °C and 5 % CO2, following which supernatants 
were recovered and frozen for later testing of cytokines. For maturation markers expression, after 
24 h incubation with the various formulations, BMDCs were washed with PBS, incubated with 
anti-CD16/CD32 (BD Biosciences), and then stained with fluorophore-labelled antibodies 
against CD11c, MHC-II, CD80, CD86 and CCR7 (Biolegend), following the manufacturer’s 
instructions. Finally, cells were washed with FACS buffer, resuspended in 200 µL of FACS 
buffer and analyzed by flow cytometry. The DC population was defined as CD11c+ MHC-II+, 
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and maturation markers expression was analyzed into this gated population. Isotype controls 
were included in each assay. 
Quantification of cytokines and antibody production by ELISA. IL-6 and IL-12 were 
measured in cell supernatants using sandwich ELISA following the manufacturer’s instructions 
(murine IL-6 mini EDK ELISA kit, R&D Systems; murine IL-12 mini EDK ELISA kits, 
Peprotech). A 4-parameter sigmoidal (logistic) standard curve was used to quantify cytokines 
(GraphPad Prism 5 software). Results are expressed as mean ± SEM in pg/mL or ng/mL. Anti-
OVA IgG1, IgG2c and IgGt antibodies were measured in blood serum using indirect ELISA. Flat 
bottom 96 well EIA/RIA plates (Corning) were covered with 50 µL/well of OVA diluted in PBS 
to a final concentration of 0.04 mg/mL. The samples of blood serum were obtained from 
immunized mice by facial vein puncture and centrifuged at 13000 × g for 5 min to remove the 
cellular content of the blood. The concentrations of antigen-specific antibodies were determined 
with HRP-conjugated anti-mouse IgG1, IgG2c and IgGt antibodies (BioRad) diluted 1:4000, 
1:10000 and 1:500 in PBS, respectively. The results were expressed as the log10 value of the 
reciprocal of the endpoint dilution which gave an optical density (O.D.) of 0.2 or above, after the 
subtraction of the background levels.  In both ELISA types, the measurement of each sample was 
conducted in duplicate. Absorbance measurements were carried out in a TECAN Genios Pro 
96/384 microplate reader at 450-550 nm.  
In vivo immunization and cancer immunotherapy studies. Animals were cared for and 
handled in compliance with the Guidelines for Accommodation and Care of Animals (European 
Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes) and internal guidelines, and all the experimental procedures were approved by the 
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appropriate local authorities. All animal were housed in ventilated cages and fed on a standard 
diet ad libitum.  
For the analysis of innate immune responses, C57BL/6J female mice (6-8 weeks old) were 
vaccinated with the various formulations diluted in PBS by injection (40 µL/mouse) into the 
hock (3 µg polyIC/mouse, 1 µg imiquimod/mouse and 4.8 µg ZnSPION/mouse). After 24 h, the 
spleen and inguinal and popliteal LNs were harvested and processed as described previously[70] 
for further analysis of the maturation of DC and NK cellular populations. Briefly, 1 × 106 
cells/well diluted in RPMI-1640 were seeded in a 96-well plate and divided into two different 
staining panels. For the DC maturation analysis, cells were stained as described in the in vitro 
BMDC maturation assays, analyzing this time an additional maturation marker, CD40 
(Biolegend). NKs cells were stained with CD3, NKp46 and CD69 antibodies, and the 
corresponding isotype control (Biolegend). The NK population was defined as CD3- Nkp46+, and 
CD69 expression was analyzed into this gated population. 
For assessing adaptive immune responses in vivo, C57BL/6J mice (6-8 weeks old) were 
immunized on day 0 (prime) and 14 (boost) with the different formulations injected s.c. into both 
flanks (100 µL/flank). Blood extraction was carried out by facial vein puncture at the indicated 
time points pre- and post- injection. Immunizations assessed in independent experiments with 5 
µg OVA/mouse and adjuvant doses ranging from 3-4 µg poly(I:C)/mouse, 0.5-1.3 µg 
imiquimod/mouse administered alone or with micellar delivery vehicles at 6-10 µg/mouse 
ZnSPION and 45-55 µg/mouse SPION produced similar results. Three weeks after the last 
immunization, mice were analyzed for the percentages of SIINFEKL-specific CD8+ T-cells in 
blood, spleen and inguinal LNs, by staining with CD8 and CD3 antibodies (Biolegend) to define 
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the CD3+ CD8+ T-cell population, and PE-labelled anti-H-2kb-OVA257-264 (Immudex) to analyze 
the OVA specific T-cell percentage in each organ of interest.  
For prophylactic tumour challenge studies, vaccinated C57BL/6J female mice (6-8 weeks old) 
were challenged one week after the last immunization by s.c. injection of 3 × 105 B16-
F10(OVA) tumour cells. Mycoplasma test (Lonza) was carried out prior to injection to ensure 
that cells were free of contamination. Tumours were measured every two to three days with a 
digital caliper and volumes (V) were calculated as V (mm3) = [(short diameter)2 x (long 
diameter)]/2. Mice were considered tumour-free until dermal lesions were visible or palpable. 
For survival rate evaluation, mice were kept until sacrifice was necessary once the tumour 
reached a diameter of ≥ 15 mm or when tumour necrosis or ulceration signs appeared. 63 days 
after the first tumour challenge, healthy mice were s.c. re-challenged with 3 × 105 B16-
F10(OVA) cells. Immunizations with OVA + polyIC-R837 and mZnSPION-polyIC-R837 were 
carried out in independent experiments three times.  
Effector memory and central memory CD8+ T cell populations were defined as CD44+CD62L+ 
and CD44+CD62L-, respectively, inside the CD3+ and CD8+ double positive population. OVA 
specific T-cell percentage in this population was analyzed as previously described. To study 
intracellular IFN-γ and TNF-α and the expression of the degranulation marker, 1 × 106 cells/well 
were placed in a 96-well plate in 100 µL of RPMI-1640 medium in the presence of BD Golgi 
Stop, the anti-CD107a antibody (LAMP-1 protein) and 10 µg/mL SIINFEKL in RPMI-1640 
medium. After 5 h of incubation at 37 °C, cells were washed twice and stained with the surface 
markers (CD3 and CD8). Then, cells were fixed and permeabilised (BD Cytofix/Cytoperm 
fixation and permeabilisation kit), after which intracellular cytokine staining was performed 
(anti-INF-γ and -TNF-α antibodies). T cells were gated based on double positive for CD3 and 
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CD8 markers. Results were represented as IFN-γ and CD107a double positive or TNF-α positive 
cell percentage of total CD3+ CD8+ T cells. Isotype controls were included in intracellular 
cytokine analysis by flow cytometry assay and were not included in the figures for clarity 
purposes. Results were expressed as mean ± SEM of 5 mice per group of immunization, 
analysed individually and compared to unstimulated wells.  
For creating the B16-F10(OVA) with knock-down expression of PD-L1 (B16-F10(OVA) ∆PD-
L1), lentiviral particles for silencing the expression of PD-L1 were produced in 293T as 
described previously.[78] Cell culture supernatants were harvested, filtered through 0.45 µm 
filter and ultracentrifuged for lentivector purification. Lentiviral particles were titrated and used 
to transduce B16-F10(OVA) cells. Knockdown cells were selected by antibiotic pressure with 
increasing concentrations of puromycin. Similarly to the prophylactic immunization assays 
described above, C57BL/6J female mice (6-8 weeks old) were challenged one week after the last 
immunization by s.c. injection of 3 × 105 B16-F10(OVA) ∆PD-L1 cells. In this case, however, 
due to the slower tumour growth the re-challenge was carried out with 1.5 × 106 B16-F10(OVA) 
∆PD-L1 cells/mouse 35 days after the first challenge.  
Imaging studies. Tumours were left to settle and grow until the diameter reached around 7 - 12 
mm before imaging acquisition.  
For MR in vivo experiments, at the beginning of the experiments, mice were immunized with 
mZnSPION-pIC-R837 at a concentration of 6 mM Fe. 100 µL of sample were s.c. injected in the 
tumour vicinity. Images were acquired at times prior injection, 24 h and 48 h post-injection to 
analyze accumulation of nanoparticles. Animals were anesthetized prior to imaging using 3.5 % 
isofluorane and maintained at 1.5 – 2.5 % isoflurane in 100 % O2 and at a constant body 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
temperature of 37 °C during the whole acquisition. Experiments were performed on a 70/30 
Bruker Biospec system (Bruker Biospin GmbH, Ettlingen, Germany) using the BGA12-S mini 
imaging gradient and 40 mm inner diameter transmit/receive mouse body volumetric coil. Axial 
gradient echo experiments were performed with the following parameters: A respiration 
synchronized (TR = one respiration cycle) FLASH sequence, TE = 3 ms, FOV = 28 mm x 28 
mm, Matrix = 256 x 256, Slice Thickness = 0.75 mm, N Slices= 32 and 2 averages. Axial T2-
weighted images were acquired using the following parameters: A respiration synchronized (TR 
= 4 respiration cycles) Multi Slice Multi Echo (MSME) sequence, TE = 8, 16, 24, 32, 40, 48, 56, 
64 ms; FOV = 28 mm x 28 mm, Matrix = 128 x 128, Slice Thickness = 0.75 mm, N Slices= 9 
and 2 averages. The images were fitted into Levenberg-Margardt method to calculate T2 values 
using Bruker's Paravision 5.1 software. 
To carry out in vivo SPECT/CT studies, MNPs were labelled with Gallium-67. Radiolabelling 
was carried out using a 67Ga citrate solution purchased from Molypharma (Spain) (specific 
activity =1.4 TBq/µmol), which was first converted into 67GaCl3. Briefly, the 67Ga citrate 
solution was passed through a light silica column cartridge (Sep-Pak, Waters) to selectively 
retain the radiometal. The cartridge was washed with ultrapure water (10 mL) and 67Ga was 
finally eluted with HCl 0.1 M solution. The eluate was collected in different 100 µL fractions, 
and only those containing the maximum activity concentration were used in subsequent labeling 
experiments. The eluted 67Ga chloride solution (100 µL, c.a. 110 MBq) was then mixed with 100 
µL of mZnSPION-pIC-R837 or mSPION-OVA micelles solution and diluted up to final volume 
of 400 µL in acetate buffer (pH = 3.8 ± 0.1). After incubation at 70 °C during 30 min, the 
reaction crude was cooled down to room temperature, the labelled MNPs were separated via 
centrifugal filtration (3354 x g for 10 min) using AmiconUltracel 100k (MWCO 100 kDa) 
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centrifugal devices (Merck), and washed twice with 10 mM PBS. The retentate was recovered 
from the filter by the addition of PBS (100 µL). The total radioactivity in the filtrates and 
retentates was measured in a CRC-25R dose calibrator (Capintec, USA) in order to determine 
the incorporation efficiency. For stability studies, one batch of 67Ga-mZnSPION-pIC-R837 or 
mSPION-OVA was fractioned in different aliquots, which were incubated in the presence of 
DOTA chelating agent (c.a. 106 moles of DOTA per mole of nanoparticle) at 37 °C. At different 
time points, the samples were filtered in order to separate the NPs from the 67Ga complexed to 
DOTA, and radioactivity in the retentate and in the filtrate was measured with the CRC-25R 
dose calibrator. The dissociation of 67Ga (expressed in percentage) from the radiolabelled 
micelles at each time point was calculated as the ratio between the amount of radioactivity in the 
filter and the starting amount of radioactivity. For in vivo imaging studies, tumour bearing mice 
were immunized with 67Ga-labelled mZnSPION-pIR-R837 or mSPION-OVA dissolved in PBS 
to a concentration of 1.2 or 6 mM Fe, respectively. 50 µL of sample/mouse were s.c. injected in 
the tumour vicinity, in the ventral flank or in the hind hock. Animals were anesthetized prior to 
imaging using 3.5 % isofluorane and maintained at 1.5 – 2.5 % isoflurane in 100 % O2 during the 
whole acquisition. Whole-body SPECT/CT scans were acquired at 3 h, 24 h and 48 h post-
injection using the eXplore speCZT CT preclinical imaging system (GE Healthcare, USA). With 
the full ring detector, 360° of data were acquired by rotating the collimator 45° (45 steps, 
1°/step). Data were collected in an energy acquisition window from 125−150 keV to 84−102 
keV and acquisition times from 60 min (80 s/step) to 45 min (60 s/step). An 8-slit collimator was 
used with a field of view of 32 and 78 mm in the transaxial and axial directions, respectively. 
After each SPECT scan, CT acquisitions were performed to provide anatomical information on 
each animal. The CT acquisition consisted of 220 views in 0.88° increments around the animal 
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with 16 ms exposure per view. The X-ray tube settings were 70 kV and 32 mA. The SPECT 
images were reconstructed using the OSEM iterative algorithm (5 and 15 subsets, 3 and 5 
iterations) into 128 × 128 × 32 array with a voxel size of 0.4 × 0.4 × 2.46 mm, and were not 
corrected for scatter and attenuation. The CT images were reconstructed using a cone beam 
filtered back-projection Feldkamp algorithm into 437 × 437 × 523 array with a voxel size of 0.2 
× 0.2 × 0.2 mm. At the end of the scanning procedure, the mice were culled by cervical 
dislocation and organs of interest removed. Analysis of the injected dose percentage per organ 
was performed by measuring their activity with a WIZARD22470 Automatic Gamma Counter 
(PerkinElmer). 
Statistical analysis. Data presented as mean ± SEM. The differences between the control and the 
experimental groups were assessed using two-tailed unpaired Student’s t tests and the differences 
among groups > 2 by one-way or two-way ANOVA (GraphPad Prism, GraphPad Software, La 
Jolla, CA). P values of less than 0.05 were considered statistically significant. 
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